| Exec date | Filing date | Company | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Jun 3, 2025 | Jun 5, 2025 | Anika Therapeutics, Inc. | CFO | Sell | 46.3 | -3,769 | -27.63% | ✗ | $43.7K |
| Mar 31, 2024 | Apr 2, 2024 | VSE CORP | CFO | Sell | 87.5 | +1,407 | 2.51% | ✗ | $91.7K |
| Mar 10, 2024 | Mar 12, 2024 | VSE CORP | CFO | Sell | 90.0 | +3,922 | 5.08% | ✗ | $227.7K |
| Mar 31, 2023 | Apr 4, 2023 | VSE CORP | CFO | Sell | 83.8 | +602 | 3.37% | ✗ | $36.5K |
| Mar 10, 2023 | Mar 14, 2023 | VSE CORP | CFO | Sell | 78.8 | +919 | 1.48% | ✗ | $39.6K |
| Nov 9, 2022 | Nov 10, 2022 | VSE CORP | CFO | Sell | 95.0 | +3,494 | 32.59% | ✗ | $73.1K |
| Mar 31, 2022 | Apr 4, 2022 | VSE CORP | CFO | Sell | 86.3 | +551 | 5.60% | ✗ | $35.8K |
| Mar 11, 2022 | Mar 14, 2022 | VSE CORP | CFO | Sell | 67.5 | +45 | 0.53% | ✗ | $822.7 |
| Mar 16, 2021 | Mar 17, 2021 | VSE CORP | CFO | Sell | 77.5 | +43 | 1.32% | ✗ | $994.1 |